BioAgilytix Labs, which has been expanding its operations, has landed an investment from Boston private equity firm Riverside Partners.

Financial terms of Riverside’s investment in the Durham contract research organization were not disclosed.

In a statement, Riverside said that its investment was completed in partnership with BioAgilytix’s founders and management team.

“The Riverside team has a great understanding of how to scale a pharmaceutical services business, and the two organizations have a very strong cultural fit,” Jim Petrilla , co-founder and CEO of BioAgilytix said in a statement.

BioAgilytix specializes in conducting bioanlytic testing on large molecule biologic drugs. The company, which launched in 2008, provides outsourced laboratory services for companies in the pharmaceuticals, biotechnology and agriculture industries. BioAgilytix announced in April that it had quadrupled its space in Durham to more than 30,000 square feet to add lab space and increase capacity.

Petrilla is the former of CEO of Durham stem cell therapies company Aldagen. After leaving Aldagen, he became an executive at TriPath Imaging, a Burlington cancer diagnostics company that was acquired by Becton Dickinson for about $350 million in 2006.

Riverside is currently investing from its fifth fund, focusing on companies primarily in health care and technology. The firm manages $1 billion of equity capital and looks to invest in companies with revenues between $20 million and $200 million in revenue.